Therapeutic Advances in Leishmaniasis: an integrative review of conventional strategies and pharmacological innovations
DOI:
https://doi.org/10.5281/zenodo.17681399Keywords:
Leishmaniasis, Therapy, Pharmacological innovationsAbstract
This integrative review summarizes the main therapeutic advances for leishmaniasis published between 2016 and 2023. The findings indicate that although antimonials, amphotericin B, and miltefosine remain the primary treatment options, their effectiveness is increasingly compromised by drug resistance, toxicity, and operational limitations in endemic regions. At the same time, significant progress has been achieved with emerging strategies such as nanocarriers, controlled-release systems, synthetic and marine-derived compounds, drug repurposing, and immunomodulatory approaches. These developments highlight substantial scientific progress; however, most innovations remain in preclinical stages, underscoring the need for translational research and robust clinical trials. Overall, the evidence points to a promising therapeutic landscape, with growing potential for incorporation of new technologies into clinical practice.
References
ADRIAENSEN, W.; DORLO, T. P. C.; VANHAM, G. et al. Immunomodulatory therapies for Leishmania–HIV coinfection. Frontiers in Immunology, v. 8, 2018. DOI: 10.3389/fimmu.2017.01943.
ÁLVAREZ-BARDÓN, M.; PÉREZ-PERTEJO, Y.; ORDÓÑEZ, C. et al. Marine-derived compounds as antiparasitic agents. Marine Drugs, v. 18, n. 4, 2020. DOI: 10.3390/md18040187.
ALVES, F.; BILBE, G.; BLESSON, S. et al. Advances, challenges, and research gaps in visceral leishmaniasis treatment. Clinical Microbiology Reviews, v. 31, 2018. DOI: 10.1128/CMR.00048-18.
BENAIM, G.; PANIZ-MONDOLFI, A. E.; SORDILLO, E. M.; MARTÍNEZ-SOTILLO, N. Advances in antiparasitic drug development, including amiodarone repositioning. Current Medicinal Chemistry, v. 28, 2021. DOI: 10.2174/1381612826666200928161403.
DOMÍNGUEZ-ASENJO, B.; GUTIÉRREZ-CORBO, C.; ÁLVAREZ-BARDÓN, M. et al. Enzyme inhibitors as antileishmanial candidates. ACS Infectious Diseases, v. 7, 2021. DOI: 10.1021/acsinfecdis.1c00139.
GOYAL, V.; MAHAJAN, R.; PANDEY, K. et al. Field efficacy of visceral leishmaniasis treatments in real-world settings. PLoS Neglected Tropical Diseases, v. 12, n. 8, 2018. DOI: 10.1371/journal.pntd.0006830.
HENRIQUEZ-FIGUEREO, A.; ALCON, M.; MORENO, E. et al. Novel bioorganic derivatives with antiparasitic activity. Bioorganic Chemistry, v. 137, 2023. DOI: 10.1016/j.bioorg.2023.106624.
KOUR, P.; SAHA, P.; SHARMA, D. K.; SINGH, K. Biopolymeric controlled-release systems against Leishmania. International Journal of Biological Macromolecules, v. 240, 2023. DOI: 10.1016/j.ijbiomac.2023.128401.
MELO, M. G. N.; REINO, I. B. D. S. M.; VAITKEVICIUS-ANTÃO, V. et al. Development of antiparasitic drug-delivery nanosystems. International Journal of Pharmaceutics, v. 632, 2023. DOI: 10.1016/j.ijpharm.2023.122615.
MELO, M. G. N.; REINO, I. B. D. S. M.; VAITKEVICIUS-ANTÃO, V. et al. Evaluation of immunomodulatory therapies against Leishmania. Immunobiology, v. 228, 2023. DOI: 10.1016/j.imbio.2023.152779.
MENDES, K. D. S.; SILVEIRA, R. C. C. P.; GALVÃO, C. M. Revisão integrativa: método de pesquisa para a incorporação de evidências na saúde e na enfermagem. Texto & Contexto Enfermagem, v. 17, n. 4, p. 758-764, 2008.
MOURI, O.; MELENOTTE, C.; GUÉRY, R. et al. Therapeutic failures and resistance in endemic leishmaniasis areas. PLoS Neglected Tropical Diseases, v. 17, 2023. DOI: 10.1371/journal.pntd.0011492.
PATERSON, S.; FAIRLAMB, A. H. Nitroheterocyclic compounds as antiparasitic agents. Current Medicinal Chemistry, v. 26, 2019. DOI: 10.2174/0929867325666180426164352.
PEREIRA, C. A.; SAYÉ, M.; REIGADA, C. et al. Computational strategies for antiparasitic drug discovery. Parasitology, v. 147, 2020. DOI: 10.1017/S0031182020000207.
PEREIRA, V.; BARROS, N. B.; MACEDO, S. R. A. et al. Hydrophobic drug-releasing wound dressings for cutaneous leishmaniasis. Journal of Parasitic Diseases, v. 43, 2019. DOI: 10.1007/s12639-019-01162-y.
ROATT, B. M.; CARDOSO, J. M. O.; BRITO, R. C. F. et al. Microbial bioprocess optimization for antiparasitic compound production. Applied Microbiology and Biotechnology, v. 104, 2020. DOI: 10.1007/s00253-020-10856-w.
SIMÕES, S.; CARVALHEIRO, M.; GASPAR, M. M. Lipid nanocarriers for cutaneous leishmaniasis and Buruli ulcer. Current Drug Delivery, v. 13, 2016. DOI: 10.2174/1381612822666160701083812.
SOUSA-BATISTA, A. J.; LIMA, W. P.; RÉ, M. I.; ROSSI-BERGMANN, B. Implantable microparticles of amphotericin B for cutaneous leishmaniasis. International Journal for Parasitology: Drugs and Drug Resistance, v. 11, 2019. DOI: 10.1016/j.ijpddr.2019.06.001.
SUNDAR, S.; SINGH, A. Current and novel therapies for visceral leishmaniasis. Therapeutic Advances in Infectious Disease, v. 3, 2016. DOI: 10.1177/2049936116646063.
SUNDAR, S.; SINGH, B. Emerging therapeutic targets for leishmaniasis. Expert Opinion on Therapeutic Targets, v. 22, 2018. DOI: 10.1080/14728222.2018.1472241.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Journal of Social Issues and Health Sciences (JSIHS)
This work is licensed under a Creative Commons Attribution 4.0 International License.
